Formulation of a modified-release pregabalin tablet using hot-melt coating with glyceryl behenate

被引:22
作者
Jeong, Kyu Ho [3 ]
Woo, Hye Seung [3 ]
Kim, Chae Jin [3 ]
Lee, Kyung Hwa [3 ]
Jeon, Jun Young [1 ]
Lee, Sang Young [1 ]
Kang, Jae-Hoon [1 ]
Lee, Sangkil [2 ]
Choi, Young Wook [3 ]
机构
[1] ILDONG Pharmaceut Co Ltd, Res Labs, Hwaseong Si 445170, Gyeonggi Do, South Korea
[2] Keimyung Univ, Coll Pharm, Daegu 704701, South Korea
[3] Chung Ang Univ, Coll Pharm, Drug Delivery Res Lab, Seoul 156756, South Korea
基金
新加坡国家研究基金会;
关键词
Pregabalin; Glyceryl behenate; Hot-melt coating; Drug release; Pharmacokinetic; Stability; CONTROLLED DRUG-RELEASE; COMPRITOL(R) 888 ATO; SUSTAINED-RELEASE; PARTIAL SEIZURES; CALCIUM-CHANNEL; DOSE-RESPONSE; GABAPENTIN; TRANSPORT; MATRICES; AMYGDALA;
D O I
10.1016/j.ijpharm.2015.08.057
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A modified-release (MR) tablet of the anti-anxiety drug pregabalin (PRE) was prepared by hot-melt coating PRE with glyceryl behenate (GB) as a release retardant and compressing to form a matrix with microcrystalline cellulose (MCC) as a hydrophilic diluent. GB-coated PRE had a size in the range of 177-290 mm with good to acceptable flowability. Tablet hardness decreased slightly as GB content increased. PRE release from the tablet matrices was successfully modified by altering the ratio of MCC and GB, and it was found that dissolution-or diffusion-controlled release depended on the amount of GB used. Drug release was pH-independent. An accelerated stability test on the most promising MR tablet at 40 degrees C and 75% relative humidity for 6 months showed no significant changes in PRE content, and the occurrence of total impurities-including PRE-lactam-was within acceptable limits. After oral administration of the selected MR tablet or a commercial IR capsule (Lyrica) to healthy human volunteers, pharmacokinetic parameters including T-max, C-max, AUC(0-24), and T-1/2 were compared. The confidence interval of AUC(0-24) was within the adequate range, but that of C-max was inadequate. This study demonstrated the potential use of GB for PRE-containing MR formulations. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 32 条
[1]  
[Anonymous], 2004, 21446 NDA CDER US FO
[2]   Pregabalin add-on treatment: A randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures [J].
Arroyo, S ;
Anhut, H ;
Kugler, AR ;
Lee, CM ;
Knapp, LE ;
Garofalo, EA ;
Messmer, S .
EPILEPSIA, 2004, 45 (01) :20-27
[3]   Compritol® 888 ATO:: an innovative hot-melt coating agent for prolonged-release drug formulations [J].
Barthelemy, P ;
Laforêt, JP ;
Farah, N ;
Joachim, J .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1999, 47 (01) :87-90
[4]   Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: An ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice [J].
Bian, F ;
Li, Z ;
Offord, J ;
Davis, MD ;
McCormick, J ;
Taylor, CP ;
Walker, LC .
BRAIN RESEARCH, 2006, 1075 :68-80
[5]   Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers [J].
Bockbrader, Howard N. ;
Radulovic, Louis L. ;
Posvar, Edward L. ;
Strand, James C. ;
Alvey, Christine W. ;
Busch, Janice A. ;
Randinitis, Edward J. ;
Corrigan, Brian W. ;
Haig, George M. ;
Boyd, Rebecca A. ;
Wesche, David L. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (08) :941-950
[6]  
Bourne David W. A., 2002, VVolume 121, P67
[7]  
Bryans JS, 1999, MED RES REV, V19, P149, DOI 10.1002/(SICI)1098-1128(199903)19:2<149::AID-MED3>3.0.CO
[8]  
2-B
[9]  
Chien Y.W., 1992, NOVEL DRUG DELIVERY
[10]   Modeling and comparison of dissolution profiles [J].
Costa, P ;
Manuel, J ;
Lobo, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :123-133